Literature DB >> 21119110

Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease.

Fang Zhao1, Yi Zhang, Hao Wang, Min Jin, Shan He, Yufang Shi, Yajun Guo, Yanyun Zhang.   

Abstract

Graft-versus-host disease (GVHD), a life-threatening complication after allogeneic hematopoietic stem cell transplantation, is caused by alloreactive donor T cells that trigger host tissue damage. The inflammatory environment inside recipients is critical for GVHD pathogenesis, but the underpinning mechanisms remain elusive. Using mouse model of human GVHD, we demonstrate osteopontin (OPN), a potent proinflammatory cytokine, plays an important role in regulating activation, migration, and survival of alloreactive T cells during GVHD. OPN was significantly elevated after irradiation and persisted throughout the course of GVHD. Blockade of OPN attenuated GVHD with reduced accumulation of donor T cells in recipient organs. Amelioration was the result of migration and survival suppression caused by anti-OPN treatment on donor-derived T cells for 2 reasons. First, OPN promoted the migration and infiltration of naive and alloreactive CD8(+) T cells into host organs. Second, it also facilitated activation and viability of donor-derived CD8(+) T cells via synergizing with T-cell receptor/CD3 signaling. Finally, anti-OPN treatment retained graft-versus-leukemia effect of alloreactive CD8(+) T cells. This study demonstrates, to our knowledge for the first time, the critical effect of OPN in the initiation and persistence of CD8(+) T cell-mediated GVHD and validates OPN as a potential target in GVHD prevention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21119110      PMCID: PMC3056597          DOI: 10.1182/blood-2010-04-281659

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks.

Authors:  A W O'Regan; G J Nau; G L Chupp; J S Berman
Journal:  Immunol Today       Date:  2000-10

Review 2.  T-cell function and migration. Two sides of the same coin.

Authors:  U H von Andrian; C R Mackay
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

3.  Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis.

Authors:  Guangjie Chen; Xin Zhang; Runsheng Li; Lei Fang; Xiaoyin Niu; Yingxia Zheng; Dongyi He; Rong Xu; Jingwu Z Zhang
Journal:  Arthritis Rheum       Date:  2010-10

4.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

Review 5.  Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis.

Authors:  Jian Hong; George J Hutton
Journal:  J Interferon Cytokine Res       Date:  2010-10       Impact factor: 2.607

6.  Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy.

Authors:  M Takemoto; K Yokote; M Yamazaki; A L Ridall; W T Butler; T Matsumoto; K Tamura; Y Saito; S Mori
Journal:  Ann N Y Acad Sci       Date:  2000-05       Impact factor: 5.691

7.  Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.

Authors:  Tangsheng Yi; Ying Chen; Lin Wang; Gong Du; Daniel Huang; Dongchang Zhao; Heather Johnston; James Young; Ivan Todorov; Dale T Umetsu; Lieping Chen; Yoichiro Iwakura; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

8.  A functional motif QLYxxYP is essential for osteopontin induced T lymphocyte activation and migration.

Authors:  Jianxin Dai; Zhiguo Cao; Yanshen Kang; Kexing Fan; Guanghui Ji; Haiou Yang; Huajing Wang; Jie Gao; Hao Wang; Yajun Guo
Journal:  Biochem Biophys Res Commun       Date:  2009-01-29       Impact factor: 3.575

Review 9.  Regulation of T-helper-cell lineage development by osteopontin: the inside story.

Authors:  Harvey Cantor; Mari L Shinohara
Journal:  Nat Rev Immunol       Date:  2009-02       Impact factor: 53.106

10.  Osteopontin as two-sided mediator of intestinal inflammation.

Authors:  Katja Heilmann; Ute Hoffmann; Ellen Witte; Christoph Loddenkemper; Christian Sina; Stefan Schreiber; Claudia Hayford; Pamela Holzlöhner; Kerstin Wolk; Elianne Tchatchou; Verena Moos; Martin Zeitz; Robert Sabat; Ursula Günthert; Bianca Maria Wittig
Journal:  J Cell Mol Med       Date:  2008-07-04       Impact factor: 5.310

View more
  19 in total

1.  An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.

Authors:  John D Klement; Amy V Paschall; Priscilla S Redd; Mohammed L Ibrahim; Chunwan Lu; Dafeng Yang; Esteban Celis; Scott I Abrams; Keiko Ozato; Kebin Liu
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 2.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

3.  The possible roles of OPN-regulated CEACAM1 expression in promoting the survival of activated T cells and the apoptosis of oral keratinocytes in oral lichen planus patients.

Authors:  Gui-Xiang Liu; Qi Xie; Cheng-Jun Zhou; Xiao-Ying Zhang; Bo-Long Ma; Cheng-Qin Wang; Feng-Cai Wei; Xun Qu; Shan-Zhen Sun
Journal:  J Clin Immunol       Date:  2011-06-14       Impact factor: 8.317

4.  Myelopoiesis embraces its inner weakness.

Authors:  Motti Gerlic; Ben A Croker
Journal:  Nat Immunol       Date:  2017-08-22       Impact factor: 25.606

5.  Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.

Authors:  Qingrong Huang; Shan He; Yuanyuan Tian; Yuting Gu; Pan Chen; Changhong Li; Jiefang Huang; Yongnian Liu; Hongshuang Yu; Min Jin; Shaoyan Hu; Qing Tong; Anqi Ma; Jian Jin; Elizabeth Hexner; Henry Fung; Ran Reshef; Yi Zhang; Yanyun Zhang
Journal:  Blood       Date:  2017-02-28       Impact factor: 22.113

Review 6.  Osteopontin and Transplantation: Where Are We Now?

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-21       Impact factor: 4.291

Review 7.  Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.

Authors:  Meng Lv; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2012-03-18       Impact factor: 17.388

8.  Osteopontin promotes dendritic cell maturation and function in response to HBV antigens.

Authors:  Guangying Cui; Jianing Chen; Jianqin He; Chong Lu; Yingfeng Wei; Lin Wang; Xuejun Xu; Lanjuan Li; Toshimitsu Uede; Hongyan Diao
Journal:  Drug Des Devel Ther       Date:  2015-06-12       Impact factor: 4.162

9.  Kinetics of IFN-γ and IL-17 Production by CD4 and CD8 T Cells during Acute Graft-versus-Host Disease.

Authors:  Ji-Min Ju; Hakmo Lee; Keunhee Oh; Dong-Sup Lee; Eun Young Choi
Journal:  Immune Netw       Date:  2014-04-21       Impact factor: 6.303

Review 10.  Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.

Authors:  Hadir Shakshouk; Eric R Tkaczyk; Edward W Cowen; Rokea A El-Azhary; Shahrukh K Hashmi; Saad J Kenderian; Julia S Lehman
Journal:  Transplant Cell Ther       Date:  2021-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.